Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type | NCT00036114 | Trialant
CompletedInterventionalPhase 3Updated Nov 11, 2013
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov ID
NCT00036114
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Nov 11, 2013Estimated
Start Date
Mar 2000
Primary Completion Date
Aug 2003Actual
Completion Date
Aug 2003Actual
Brief Summary
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
Alzheimer Disease
aripiprazole
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Institutionalized patients with Alzheimer's
Primary Purpose
Treatment
No central contacts
There are no central contacts for this study.
Local Institution
Tuscaloosa, Alabama, United States
Local Institution
Scottsdale, Arizona, United States
Local Institution
Cerritos, California, United States
Local Institution
Granada Hills, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
San Diego, California, United States
Local Institution
Torrance, California, United States
Local Institution
Denver, Colorado, United States
Local Institution
Hamden, Connecticut, United States
Local Institution
Miami, Florida, United States
Local Institution
North Miami Beach, Florida, United States
Local Institution
West Palm Beach, Florida, United States
Local Institution
Atlanta, Georgia, United States
Local Institution
Augusta, Georgia, United States
Local Institution
Macon, Georgia, United States
Local Institution
Honolulu, Hawaii, United States
Local Institution
North Chicago, Illinois, United States
Local Institution
Springfield, Illinois, United States
Local Institution
New Orleans, Louisiana, United States
Local Institution
Shreveport, Louisiana, United States
Local Institution
Baltimore, Maryland, United States
Local Institution
Newton Center, Massachusetts, United States
Local Institution
Springfield, Massachusetts, United States
Local Institution
Wellesley Hills, Massachusetts, United States
Local Institution
Lyons, New Jersey, United States
Local Institution
Albany, New York, United States
Local Institution
Lawrence, New York, United States
Local Institution
Montrose, New York, United States
Local Institution
Northport, New York, United States
Local Institution
White Plains, New York, United States
Local Institution
Raleigh, North Carolina, United States
Local Institution
Beachwood, Ohio, United States
Local Institution
Portland, Oregon, United States
Local Institution
Hershey, Pennsylvania, United States
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Wichita Falls, Texas, United States
Local Institution
Bennington, Vermont, United States
Local Institution
Charlottesville, Virginia, United States
Local Institution
Seattle, Washington, United States
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY